Lung Cancer Clinical Trials & Research at Providence Medical Group

The two main types of lung cancer are non-small cell lung cancer and small cell lung cancer. The types are based on the way the cells look under a microscope. Non-small cell lung cancer is much more common than small cell lung cancer. Tobacco smoking is the most common cause of lung cancer.

Providence Medical Group is currently enrolling patients for the following lung cancer clinical trials:

Non-Small Cell Lung Cancer
Small Cell Lung Cancer


Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Another Anti-cancer Therapy for Treatment of Recurrent (Non-small Cell) Lung Cancer

Treatment: GEN1046 alone or with Pembrolizumab
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT05117242
Sponsor: Genmab


A Phase lb Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03)

Treatment agent: Trastuzumab deruxtecan + durvalumab, carboplatin, or pemetrexed
PI: Ian Anderson, MD
Study Coordinator: Melissa Phillips // Melissa.Phillips2@stjoe.org// (707) 521-3833 ext. 1313
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT03328026
Sponsor: AstraZeneca


Study to Assess the Effect of PF_06946860 on Appetite Following Subcutaneous Administration to Patients with Anorexia and Advanced Cancer

Treatment agent: PF-06946860
PI: Sara Keck, MD
Study Coordinator: Tracy Foster
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04803305?term=PF-06946860&draw=2&rank=2
Sponsor: Pfizer


A Phase III, Randomized, Multicenter, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Comination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA)

Treatment agent: Chemotherapy + Osimbertinib or placebo
PI: Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links: A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov
Sponsor: AstraZeneca


Non-Small Cell Lung Cancer

A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)

Treatment agent: Canakinumab or Placebo
PI: Ian Anderson, MD
Study Coordinator: Tracy Foster
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04642469?term=04642469&draw=2&rank=1
Sponsor: Novartis Pharmaceuticals


A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Treatment agent: MRTX849 + pembrolizumab
PI: Manasa Vulchi, MD
Study Coordinator: Tracy Foster
Resources and Links: clinicaltrials.gov NCT No: NCT04613596
Sponsor: Mirati Therapeutics, Inc.


Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)

Treatment agent: Zimberelimab with or without domvanalimab and/or etrumadenant
PI: Ian Anderson, MD
Study Coordinator: Camille Shaffer
Resources and Links: clinicaltrials.gov NCT No: NCT04262856
Sponsor: Arcus Biosciences, Inc.


A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1)

Treatment agent: Durvalumab + chemotherapy
PI: Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links: clinicaltrials.gov NCT No: NCT04385368
Sponsor: AstraZeneca


Small Cell Lung Cancer

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy (MERMAID-2)

Treatment agent: Durvalumab or placebo
PI: Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04642469?term=04642469&draw=2&rank=1
Sponsor: AstraZeneca


A Phase II, Open-label, Single-arm Study of Berzosertib (M6620) in Combination With Topotecan in Participants With Relapsed Platinum-resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

Treatment agent: Berzosertib, Topotecan Hydrochloride
PI: Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04768296?term=DDRiver&draw=2&rank=1
Sponsor: EMD Serono


Seer-020201 (Pulmonary Nodules)

Treatment: Durvalumab + Tremelimuab, Durvalumab, and Placebo
PI: Manasa Vulchi, MD
Study Coordinator: Melissa​
NCT – NA


A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

Treatment: MRTX849, Docetaxel
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04685135?term=krystal-12&draw=2&rank=1
Sponsor: Mirati Therapeutics


A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy (MERMAID-2) (AstraZeneca D910MC00001 MERMAID 2)

Treatment: Durvalumab or placebo
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04642469?term=04642469&draw=2&rank=1
Sponsor: AstraZeneca


A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) (Novartis CACZ885T2301 CANOPY )

Treatment: Canakinumab or Placebo
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT03447769?term=03447769&draw=2&rank=1
Sponsor: Novartis Pharmaceuticals


A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology(EMD Serono MS201923-0050 DDRiver )

Treatment: Berzosertib, Topotecan Hydrochloride
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT03896503?term=03896503&draw=2&rank=1
Sponsor: EMD Serono


A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology (EMD Serono MS201923-0050 DDRiver )

Treatment: Berzosertib, Topotecan Hydrochloride
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT03896503?term=03896503&draw=2&rank=1
Sponsor: EMD Serono


A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation (Mirati 849-012 KRYSTAL-12 )

Treatment: MRTX849, Docetaxel
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04685135?term=krystal-12&draw=2&rank=1
Sponsor: Mirati Therapeutics, Inc.


A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA)

Treatment: Chemotherapy + Osimbertinib or placebo
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04351555?term=NeoADAURA&draw=2&rank=1
Sponsor:AstraZeneca


Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer (RAZORGENOMICS)

Treatment: Observational study/ Standard of care
PI: Ian Anderson, MD
Coordinator: Melissa Phillips // Melissa.Phillips2@stjoe.org// (707) 521-3833 ext. 1313
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT01817192?term=NCT01817192&draw=2&rank=1
Sponsor:Razor Genomics

Our Providers

Our Locations